
Artivion, Inc.
NYSE•AORT
CEO: Mr. James Patrick Mackin
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1993-02-12
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Contact Information
Market Cap
$2.11B
P/E (TTM)
-111.0
vs Industry 38.5
Dividend Yield (TTM)
--
52W High
$45.07
52W Low
$21.97
52W Range
2.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q2 2025 Data
Revenue
$112.97M+15.25%
4-Quarter Trend
EPS
$0.03-159.65%
4-Quarter Trend
FCF
-$7.02M-293.71%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
AVAH$2.18B
$1.46B
$1.32B
Gross Margin (Latest Quarter)
LMAT70.0%
ATEC69.6%
PRCT65.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ATEC | $2.47B | -15.1 | -251.8% | 74.2% |
| AORT | $2.11B | -111.0 | -5.5% | 1.0% |
| AVAH | $2.04B | 106.0 | -19.1% | 84.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
+5.7%
Steady Growth
4-Quarter Net Income CAGR
N/M
Profitability Shift Observed
Cash Flow Stability
50%
Cash Flow Requires Attention
Research & Insights
Reports
All Years
Form 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 8, 2025|Revenue: $112.97M+15.3%|EPS: $0.03-159.6%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 6, 2025|Revenue: $98.98M+1.6%|EPS: $-0.01-106.6%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 28, 2025|Revenue: $388.54M+9.8%|EPS: $-0.32+57.3%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 8, 2024|Revenue: $95.78M+9.0%|EPS: $-0.05-77.3%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 9, 2024|Revenue: $98.02M+9.8%|EPS: $-0.05-38.8%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 7, 2024|Revenue: $97.43M+17.1%|EPS: $0.18-154.5%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 23, 2024|Revenue: $354.00M+12.8%|EPS: $-0.75-56.3%MissForm 10-Q - Q3 2023
Period End: Sep 30, 2023|Filed: Nov 3, 2023|Revenue: $87.85M+14.3%|EPS: $-0.24-29.4%Miss